The main barrier in the progress of clinical gene therapy is the absence of a safe and efficient vector system with regulatable and tissue-specific characteristics. However, progress has been made in ...

The “outdated” downstream separation technologies used in viral vector manufacturing are a major cause of the industry’s struggles to keep up with growing demand from the gene therapy sector. At least ...